Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

BSA Behavioral Health announced it is expanding its mental health services to include Spravato (esketamine) nasal spray, for ...

RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe treatment-resistant depression in Scotland but intravenous ketamine has not, though it ...

However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine. This article examines Medicare coverage for ketamine infusion, coverage ...

A futuristic fix for depression is here — and it doesn’t involve prescription drugs or a shrink. The first-of-its-kind solution from GrayMatters Health uses something called “self ...

Original Medicare covers infusions that a healthcare professional administers. However, it does not generally cover ketamine infusions for mental health conditions such as depression and anxiety ...